1580 Purpose: For dosimetry after 177 Lu-DOTATATE therapy, the sequential SPECT/CT
imaging is required to obtain time-integrated activity in interested region. This procedure …

3198 Introduction: Post-therapeutic dosimetry after 177 Lu-DOTATATE is required for the
optimization of further therapy. The voxel-based dosimetry using sequential SPECT/CT …

2820 Introduction: A major roadblock to dosimetry adoption is the burden of multiple image
acquisitions over several days. This study evaluates the accuracy of a single-timepoint …

P37 Introduction: This study evaluates the feasibility of single-timepoint dosimetry (STPD) for
radiopharmaceutical therapy with a 24-hour SPECT/CT. There are often limitations in …

Background The number of SPECT/CT time-points is important for accurate patient dose
estimation in peptide receptor radionuclide therapy. However, it may be limited by the …

2817 Introduction: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has
become a popular treatment option for neuroendocrine tumours (NETs) in recent years …

1568 Purpose: 177 Lu-DOTATATE therapy is regarded as a proper option for
neuroendocrine tumor (NET) because 177 Lu has good targeting performance and suitable …

1632 Objectives: For peptide receptor radionuclide therapy, dosimetry of tumors (targets)
and healthy structures (organs at risk) is often determined at a population level. Patients …

Background Single time point measurement approach and hybrid dosimetry were proposed
to simplify the dosimetry process. It is anticipated that utilizing patient‐specific S‐value …

Estimation of the time-integrated activity (TIA) for dosimetry from imaging at a single time
point (STP) facilitates the clinical translation of dosimetry-guided radiopharmaceutical …